FASN-IN-8
FASN-IN-8 is a fatty acid synthase (FASN) inhibitor. FASN-IN-8 inhibits FASN-mediated de novo lipogenesis. FASN-IN-8 blocks PI3K/AKT pathway activation, inhibits cancer cells proliferation, migration and invasion. FASN-IN-8 induces apoptosis and ROS production. FASN-IN-8 can be used for the research of hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Formula: C55H63N3O17
- Molecular Weight:1038.10
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Caspase Isoforms
More
Biological Activity
|
Caspase 3 |
Caspase 9 |
FASN-IN-8 (Compound 4) (48 h) potently inhibits proliferation of Hep-G2 hepatocellular carcinoma cells with an IC50 of 0.47 μM, shows lower activity against Huh-7 cells with an IC50 of 1.43 μM, and has high selectivity for cancer cells over normal HUVECs with a selectivity index of 260[1].
FASN-IN-8 (0.094-2.35 μM; 24 h) inhibits colony formation of Hep-G2 cells in a concentration-dependent manner[1].
FASN-IN-8 (0.094-2.35 μM; 24 h) dose-dependently inhibits FASN activity in Hep-G2 cells[1].
FASN-IN-8 (0.094-2.35 μM; 48 h) induces caspase-mediated apoptosis in Hep-G2 cells in a concentration-dependent manner, with upregulated cleaved-caspase-3 and cleaved-caspase-9 expression[1].
FASN-IN-8 (0.094-2.35 μM; 48 h) suppresses the PI3K/AKT signaling pathway in Hep-G2 cells in vitro in a concentration-dependent manner[1].
FASN-IN-8 (0.094-2.35 μM; 3 h) induces dose-dependent reactive oxygen species production in Hep-G2 cells at 0.094, 0.47, and 2.35 μM[1].
FASN-IN-8 (0.094-2.35 μM; 48 h) dose-dependently inhibits migration of Hep-G2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human Hep-G2 hepatocellular carcinoma cells
-
Concentration:0.094 μM, 0.47 μM, 2.35 μM
-
Incubation Time:48 h (flow cytometry; Western blot)
-
Result:Significantly increased the proportion of apoptotic Hep-G2 cells in a concentration-dependent manner.
Upregulated expression of cleaved-caspase-3 and cleaved-caspase-9 in a concentration-dependent manner, indicating activation of caspase-dependent apoptotic pathways.
-
Cell Line:human Hep-G2 hepatocellular carcinoma cells
-
Concentration:0.094 μM, 0.47 μM, 2.35 μM
-
Incubation Time:48 h
-
Result:Induced dose-dependent reductions in p-PI3K and p-AKT expression.
Caused significant decreases observed at 0.47 μM and 2.35 μM compared to control.
Chemical Information
-
Molecular Weight 1038.10
-
Formula C55H63N3O17
-
SMILES
O=C1C2=C(O)C([C@@H]3O[C@H](CO)[C@@H](O)[C@@H](O)[C@H]3O)=C(OCCCCC(NC4=CC=C(OC)C=C4)=O)C=C2OC5=C1C=C(OCCCCC(NC6=CC=C(OC)C=C6)=O)C(OCCCCC(NC7=CC=C(OC)C=C7)=O)=C5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
FASN-IN-8 Related Classifications
HY-181801 Related Classifications
Powered by Bioz